知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.018 秒)

    CRYSTALLINE FORMS OF LESINURAD AND ITS SODIUM SALT
    3.
    发明申请
    CRYSTALLINE FORMS OF LESINURAD AND ITS SODIUM SALT 审中-公开
    LESINURAD及其钠盐的结晶形式

    公开(公告)号：US20160297778A1

    公开(公告)日：2016-10-13

    申请号：US15038470

    申请日：2014-11-20

    申请人： CRYATAL PHARMATECH CO., LTD. ,  SUZHOU PENGXU PHARMATECH CO., LTD.

    发明人： Minhua CHEN ,  Yanfeng ZHANG ,  Chaohui YANG ,  Xiaoyu ZHANG ,  Peng WANG ,  Pixu LI

    IPC分类号： C07D249/12

    CPC分类号： C07D249/12 ,  C07B2200/13

    摘要： Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

    摘要翻译： 新型结晶形式的维兰定和其钠盐，其制备方法，包含这些新形式的药物组合物及其用于治疗或延缓与尿酸转运蛋白1（URAT1）蛋白的活性相关的疾病或病症的进展或发作的用途是 披露 这些新颖的形式通过X射线粉末衍射，差示扫描量热法等技术表征。 它们可以容易地制备并且由于其易于处理和优异的药理性质而适合制备固体剂型。

    CRYSTALLINE FORM I OF IBRUTINIB
    4.
    发明申请
    CRYSTALLINE FORM I OF IBRUTINIB 有权
    IBRUTINIB的结晶形式

    公开(公告)号：US20170002009A1

    公开(公告)日：2017-01-05

    申请号：US15100247

    申请日：2014-11-26

    申请人： CRYSTAL PHARMATECH INC. ,  SUZHOU PENGXU PHARMATECH CO., LTD.

    发明人： Minhua CHEN ,  Yanfeng ZHANG ,  Chaohui YANG ,  Xiaoyu ZHANG ,  Peng WANG ,  Pixu LI ,  Fei LU ,  Heng GE

    IPC分类号： C07D487/04

    CPC分类号： C07D487/04 ,  A61K31/519 ,  C07B2200/13

    摘要： Crystalline Form I of ibrutinib, processes for its preparation, pharmaceutical compositions comprising the new Form, and use of Form I of ibrutinib for treating or delaying diseases or disorders related to activity of Bruton's tyrosine kinase (BTK) proteins are disclosed. The novel Form was characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. It can be readily prepared and is suitable for use in the preparation of solid dosage forms.

    摘要翻译： 公开了伊布他尼的​​结晶形式I，其制备方法，包含新形式的药物组合物以及伊布他他啶的I型用于治疗或延迟与布鲁顿酪氨酸激酶（BTK）蛋白的活性相关的疾病或病症的用途。 通过X射线粉末衍射，差示扫描量热法和其他技术对新型形态进行了表征。 它可以容易地制备并且适用于制备固体剂型。

    NOVEL SALTS AND CO-CRYSTALS OF LESINURAD
    5.
    发明申请
    NOVEL SALTS AND CO-CRYSTALS OF LESINURAD 有权
    LESINURAD的新鲜水泥和水晶

    公开(公告)号：US20160347722A1

    公开(公告)日：2016-12-01

    申请号：US15106361

    申请日：2014-12-19

    申请人： CRYSTAL PHARMATECH CO., LTD. ,  CRYSTAL PHARMATECH CO., LTD. ,  SUZHOU PENGXU PHARMATECH CO., LTD.

    发明人： Minhua CHEN ,  Yanfeng ZHANG ,  Chaohui YANG ,  Xiaoyu ZHANG ,  Peng WANG ,  Pixu LI

    IPC分类号： C07D249/12 ,  C07D207/16

    CPC分类号： C07D249/12 ,  C07B2200/13 ,  C07C59/06 ,  C07D207/16

    摘要： Novel salts and cocrystals of lesinurad, processes for their preparation, pharmaceutical compositions comprising these new salt forms and co-crystals, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transport 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.

    摘要翻译： 病毒素的新型盐和共晶体，其制备方法，包含这些新盐形式和共晶体的药物组合物，以及它们用于治疗或延缓与尿酸运输1（URAT1）的活性相关的疾病或病症的进展或发作的用途 公开了蛋白质。 这些新颖的形式通过X射线粉末衍射，差示扫描量热法等技术表征。 它们可以容易地制备并且由于其易于处理和优异的药理性质而适合制备固体剂型。

    CRYSTALLINE FORMS OF ANTIDEPRESSANT DRUG SAGE-217 AND PREPARATION METHOD THEREFOR
    8.
    发明申请
    CRYSTALLINE FORMS OF ANTIDEPRESSANT DRUG SAGE-217 AND PREPARATION METHOD THEREFOR 有权

    公开(公告)号：US20220235094A1

    公开(公告)日：2022-07-28

    申请号：US17424179

    申请日：2020-01-19

    申请人： SUZHOU PENGXU PHARMATECH CO., LTD ,  ZHEJIANG EAZY PHARMCHEM CO., LTD

    发明人： Peng WANG ,  Pixu LI ,  Siping CHEN

    IPC分类号： C07J43/00

    摘要： The present application relates to crystalline form 04, crystalline form 06, crystalline form D-1, and crystalline form D-2 of an antidepressant drug SAGE-217 and a preparation method therefor and a pharmaceutical composition containing same. The crystalline form 04 has an XRPD pattern with characteristic peaks at 2theta values of 11.6±0.2°, 13.5±0.2°, 16.2±0.2°, 16.5±0.2°, and 23.2±0.2°; the crystalline form 06 has an XRPD pattern with characteristic peaks at 2theta values of 8.7±0.2°, 10.0±0.2°, 13.2±0.2°, 15.0±0.2°, 15.8±0.2°, and 17.3±0.2°; the crystalline form D-1 has an XRPD pattern with characteristic peaks at 2theta values of 7.2±0.2°, 8.6±0.2°, 13.3±0.2°, 19.6±0.2°, and 23.0±0.2°; and the crystalline form D-2 has an XRPD pattern with characteristic peaks at 2theta values of 7.3±0.2°, 8.6±0.2°, 13.4±0.2°, 19.7±0.2°, and 23.3±0.2°. The novel crystalline forms provided by the present application have good stability, and provide more choices for drug development.